Future Perspectives on CAR-T Therapies in Lymphoma

Video

Drs Goy, Ip, and Leslie close out their discussion with a look at the exciting developments and future of CAR T-cell therapies in lymphoma treatment.

Recent Videos
4 experts are featured in this series.
Related Content
The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

FDA Issues CRL for Tabelecleucel in EBV+ Lymphoproliferative Disease

Roman Fabbricatore
January 17th 2025
Article

The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

FDA Approves Acalabrutinib Combo in Previously Untreated MCL

FDA Approves Acalabrutinib Combo in Previously Untreated MCL

Tim Cortese;Ariana Pelosci
January 16th 2025
Article

The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

3 Things You Should Know About Immunotherapy in DLBCL

3 Things You Should Know About Immunotherapy in DLBCL

Matthew A. Lunning, MD;Grzegorz S. Nowakowski, MD
December 19th 2024
Article

Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.

Positive ORR Yielded by Iopofosine I 131 in R/R Waldenström Macroglobulinemia

Positive ORR Yielded by Iopofosine I 131 in R/R Waldenström Macroglobulinemia

Ashley Chan
December 13th 2024
Article

Results from the CLOVER WaM trial saw a clinical benefit rate of 98.2% in patients with Waldenström Macroglobulinemia treated with Iopofosine I 131.